Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?
Hankey
Graeme J
GJ
Department of Neurology, Royal Perth Hospital, University of Western Australia, Perth, Australia. gjhankey@cyllene.uwa.edu.au
D000804:Angiotensin II / Q000502:physiology; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008019:Life Style; D017410:Practice Guidelines as Topic; D017257:Ramipril / Q000009:adverse effects / Q000627:therapeutic use; D012306:Risk; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control*; D000077333:Telmisartan
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D004232:Diuretics; D000804:Angiotensin II; D017257:Ramipril; D000077333:Telmisartan